BRCA2 and pancreatic ductal adenocarcinoma: We also noted that ART558 sensitivity was not limited to genetically engineered DLD1.BRCA2‒/‒ cells and was also apparent in tumour cells with a naturally-occurring pathogenic BRCA2 mutation, namely CAPAN1 pancreatic ductal adenocarcinoma tumour cells (BRCA2 c.6174delT25, CAPAN1Parental, Fig. 2k).